Securities Times e Company NewspokerstraightrulesCube Pharmaceutical (003020) announced on the evening of May 20 that recently, Hefei Chengzhi Biopharmaceutical Co., Ltd., a wholly-owned subsidiary of the company, received an application for registration and marketing authorization of loxoprofen sodium oral solution issued by the State Food and Drug Administration."Acceptance Notice". Loxoprofen sodium is a phenylpropanoic acid non-steroidal anti-inflammatory drug, which has good analgesic, anti-inflammatory and antipyretic effects, especially strong analgesic effect.